NO963052L - Fremgangsmåte for å solubilisere vanskelig opplöselige farmasöytisk aktive komponenter - Google Patents

Fremgangsmåte for å solubilisere vanskelig opplöselige farmasöytisk aktive komponenter

Info

Publication number
NO963052L
NO963052L NO963052A NO963052A NO963052L NO 963052 L NO963052 L NO 963052L NO 963052 A NO963052 A NO 963052A NO 963052 A NO963052 A NO 963052A NO 963052 L NO963052 L NO 963052L
Authority
NO
Norway
Prior art keywords
pharmaceutically active
active components
poorly soluble
soluble pharmaceutically
solubilizing poorly
Prior art date
Application number
NO963052A
Other languages
English (en)
Norwegian (no)
Other versions
NO963052D0 (no
Inventor
Dadi Jamshed Dhabhar
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NO963052D0 publication Critical patent/NO963052D0/no
Publication of NO963052L publication Critical patent/NO963052L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO963052A 1994-01-24 1996-07-22 Fremgangsmåte for å solubilisere vanskelig opplöselige farmasöytisk aktive komponenter NO963052L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18557694A 1994-01-24 1994-01-24
PCT/US1995/001018 WO1995019759A1 (fr) 1994-01-24 1995-01-24 Procede pour solubiliser des agents pharmaceutiques difficilement solubles

Publications (2)

Publication Number Publication Date
NO963052D0 NO963052D0 (no) 1996-07-22
NO963052L true NO963052L (no) 1996-09-24

Family

ID=22681571

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963052A NO963052L (no) 1994-01-24 1996-07-22 Fremgangsmåte for å solubilisere vanskelig opplöselige farmasöytisk aktive komponenter

Country Status (14)

Country Link
EP (1) EP0741560A1 (fr)
JP (1) JPH09508128A (fr)
CN (1) CN1138827A (fr)
AU (1) AU706890B2 (fr)
BR (1) BR9506564A (fr)
CA (1) CA2181241C (fr)
CZ (1) CZ210496A3 (fr)
FI (1) FI962948A (fr)
MX (1) MX9602955A (fr)
NO (1) NO963052L (fr)
NZ (1) NZ279443A (fr)
PL (1) PL315635A1 (fr)
SK (1) SK96196A3 (fr)
WO (1) WO1995019759A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998058637A1 (fr) * 1996-06-20 1998-12-30 Mcneil-Ppc Analgesique a base d'acetaminophene et de diphenhydramine
ZA975444B (en) * 1996-06-20 1998-12-21 Mcneil Ppc Inc Acetaminophen and meclizine hydrochloride analgesics
FR2751875B1 (fr) * 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
US5763449A (en) * 1996-08-07 1998-06-09 Ascent Pediatrics, Inc. Pleasant-tasting aqueous liquid composition of a bitter-tasting drug
US6365180B1 (en) * 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
ATE429210T1 (de) * 1998-01-20 2009-05-15 Applied Analytical Ind Inc Orale flüssige zusammensetzungen
US20020086878A1 (en) * 1999-01-11 2002-07-04 Douglas Joseph Dobrozsi Compositions having improved stability
US6846495B2 (en) 1999-01-11 2005-01-25 The Procter & Gamble Company Compositions having improved delivery of actives
US20020082307A1 (en) * 1999-01-11 2002-06-27 Dobrozsi Douglas Joseph Compositions having improved stability
US6211246B1 (en) * 1999-06-10 2001-04-03 Mcneil-Ppc, Inc. Rapidly absorbed liquid compositions
FR2796843B1 (fr) * 1999-07-29 2003-05-09 So Ge Val Sa Composition antipyretique concentree et stabilisee a usage veterinaire destine a etre incorporee a l'alimentation des animaux ainsi que procede d'incorporation de cette composition a l'eau de boisson d'animaux
US6251426B1 (en) 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
DE10011032A1 (de) * 2000-03-07 2001-09-13 Bayer Ag Acetylsalicylsäure-Lösungen
KR20020069387A (ko) * 2001-02-26 2002-09-04 진양제약주식회사 호박산독실아민 조성물 및 이 조성물을 함유한 연질캅셀제제
MXPA04001026A (es) * 2001-07-31 2005-06-20 Wyeth Corp Formulacion de sucralosa para disimular sabores desagradables.
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
CN100379406C (zh) * 2003-09-22 2008-04-09 北京德众万全药物技术开发有限公司 一种难溶性药物微丸的制备方法及包含该微丸的制剂
CA2627292C (fr) * 2005-10-26 2012-04-17 Banner Pharmacaps, Inc. Systeme matriciel double a liberation lente a base d'excipients hydrophiles
DE102005053066A1 (de) 2005-11-04 2007-05-10 Basf Ag Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
WO2007065846A2 (fr) * 2005-12-09 2007-06-14 Basf Se Utilisation de copolymeres blocs de lactame polyvinylique et d'oxyde de polyalkylene comme solubilisants dans des composes peu solubles dans l'eau
US8637076B2 (en) 2006-06-01 2014-01-28 Cima Labs Inc. Prednisolone salt formulations
JP2008184430A (ja) * 2007-01-30 2008-08-14 Ss Pharmaceut Co Ltd ソフトカプセル
CA2690490C (fr) * 2010-01-19 2012-06-26 Accucaps Industries Limited Formulations pharmaceutiques de loratadine pour encapsulation et combinaisons associees
CA2690488C (fr) * 2010-01-19 2013-06-11 Accucaps Industries Limited Formulations pharmaceutiques de naproxen pour encapsulation molle et combinaisons associees
PT3158991T (pt) 2010-01-28 2021-06-23 Eagle Pharmaceuticals Inc Formulações de bendamustina
CA2867295C (fr) 2012-03-20 2020-08-11 Eagle Pharmaceuticals, Inc. Formulations de bendamustine
EP2827863B1 (fr) 2012-03-20 2019-01-16 Eagle Pharmaceuticals, Inc. Composition liquide destinée à être utilisée dans un méthode de traitement des états réagissant à la bendamustine chez des patients nécessitant des volumes réduits pour l'administration
CA2898408C (fr) 2013-02-28 2018-01-02 Pfizer Inc. Stabilite amelioree de compositions liquides nouvelles
GB201506755D0 (en) * 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
TWI586379B (zh) * 2015-06-29 2017-06-11 永信藥品工業股份有限公司 一種製作難溶藥物固體劑型的方法
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141961A (en) * 1991-06-27 1992-08-25 Richrdson-Vicks Inc. Process for solubilizing difficulty soluble pharmaceutical actives

Also Published As

Publication number Publication date
CA2181241C (fr) 2000-04-25
BR9506564A (pt) 1997-09-02
FI962948A0 (fi) 1996-07-23
PL315635A1 (en) 1996-11-25
NO963052D0 (no) 1996-07-22
NZ279443A (en) 1998-04-27
FI962948A (fi) 1996-07-23
MX9602955A (es) 1997-06-28
AU1607595A (en) 1995-08-08
WO1995019759A1 (fr) 1995-07-27
AU706890B2 (en) 1999-07-01
JPH09508128A (ja) 1997-08-19
EP0741560A1 (fr) 1996-11-13
SK96196A3 (en) 1997-03-05
CZ210496A3 (en) 1996-12-11
CA2181241A1 (fr) 1995-07-27
CN1138827A (zh) 1996-12-25

Similar Documents

Publication Publication Date Title
NO963052L (no) Fremgangsmåte for å solubilisere vanskelig opplöselige farmasöytisk aktive komponenter
PL300194A1 (en) Interferon conjugate, method of obtaining same and pharmaceutical composition containing it
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
DK0620828T3 (da) Cyclodextrinderivater med forøget vandopløselighed og anvendelse deraf
CA2258548A1 (fr) Derives tricycliques substitues par phenylamino, destines au traitement des maladies hyperproliferatives
NO944764D0 (no) Inklusjonskomplekser i vandige opplösninger av benzotiofenforbindelser med vannopplöselige cyklodekstriner og farmasöytiske formuleringer og fremgangsmåter
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
FR2545354B1 (fr) Composition pharmaceutique pour l'administration parenterale a base de nimodipin et procede pour sa preparation
AU661591B2 (en) 5,10-methylenetetrahydrofolic acid-cyclodextrin inclusion compounds
FI910895A0 (fi) Menetelmä terapeuttisesti käyttökelpoisen 4-(di-n-propyyli)amino-6-aminokarbonyyli-1,3,4,5-tetrahydrobentso/c,d/indolihippuraatin valmistam iseksi
AU4434189A (en) An anti-human immunodeficiency virus composition
CA2089853A1 (fr) Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses
IL129616A0 (en) Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
FR2701478B1 (fr) Dérivés de vitamine E contenant de l'azote quaternaire et procédés pour leur préparation.
GR3031118T3 (en) Novel seco-D steroids active in the cardiovascular system and pharmaceutical compositions containing same
IL129625A0 (en) Novel (-)-enantionmers of CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
ZA979650B (en) Heterocyclic compounds, compositions and uses.
ATE269693T1 (de) Abführmittel und verfahren zu deren herstellung
IT1257000B (it) Derivati dell'eserolina ad attivita` anticolinesterasica, procedimento per la loro preparazione e composizioni farmaceutiche cheli contengono.
MX9703734A (es) Composiciones orales que contienen ondansetron.
MX9601756A (es) Composicion liquida estable que contiene urato-oxidasa, y composicion liofilizada para su preparacion.
ES2150400A6 (es) Una composicion para el tratamiento de desordenes ulcerosos del tracto gastrointestinal.
HUT70840A (en) 2,2-dialkyl-2h-1-benzopiran and 2,2-dialkil-3,4-dihydro-3-hydroxy-2h-1-benzo-pyran derivatives, process for preparing them and pharmaceutical compositions comprising them as an active agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application